“Targeted” Chemotherapy for Esophageal Cancer by Joe Abdo et al.
April 2017 | Volume 7 | Article 631
OpiniOn
published: 03 April 2017
doi: 10.3389/fonc.2017.00063
Frontiers in Oncology | www.frontiersin.org
Edited by: 
John James Tentler, 
University of Colorado Denver School 
of Medicine, USA
Reviewed by: 
Joanne Lysaght, 
Trinity College Dublin, Ireland
*Correspondence:
Sumeet K. Mittal 
sumeet.mittal@dignityhealth.org
Specialty section: 
This article was submitted to 
Gastrointestinal Cancers, 
a section of the journal 
Frontiers in Oncology
Received: 26 January 2017
Accepted: 20 March 2017
Published: 03 April 2017
Citation: 
Abdo J, Agrawal DK and Mittal SK 
(2017) “Targeted” Chemotherapy for 
Esophageal Cancer. 
Front. Oncol. 7:63. 
doi: 10.3389/fonc.2017.00063
“Targeted” Chemotherapy for 
Esophageal Cancer
Joe Abdo1, Devendra K. Agrawal1 and Sumeet K. Mittal1,2*
1 Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, NE, USA, 2 Norton Thoracic 
Institute, St. Joseph’s Hospital and Medical Center, Dignity Health, Phoenix, AZ, USA
Keywords: esophageal cancer, molecular diagnostics, targeted chemotherapy, targeted therapy, immunotherapy, 
precision medicine
Due to its increasing incidence and low survival rate, esophageal cancer (EC) is now considered, 
even by non-medical professionals, as an extremely difficult cancer to beat akin to well-known 
terminal indications such as pancreatic and lung cancers. The average 5-year survival of EC is less 
than 18% and currently has the fastest rising rate of incidence of all cancers diagnosed in the United 
States (1). A number of cancer types have had double-digit improvements in survival statistics in 
the last 30 years; however, EC has not experienced a jump in the positive direction in regards to 
improved outcomes even as the number of therapeutic options has grown (2). Having analyzed 
patient management strategies of hundreds of EC patients, it is apparent that survival rates are 
unlikely to improve significantly until there is an availability of new FDA-approved anticancer and 
immunotherapy drugs. Currently, most EC patients are prescribed a combination of platinums, 
taxanes, anthracyclines, or pyrimidine analogs. Targeted therapies [anti-receptor tyrosine-protein 
kinase erbB-2 (HER2) and anti-epidermal growth factor receptor (EGFR)] are sometimes used in 
concert with chemoradiation. Immunotherapy clinical trials for EC are in their infancy, especially 
in the first-line setting. The standard of care for patients with stages II–III EC usually consists of 
chemotherapy, or chemoradiation either in the neoadjuvant or adjuvant setting of esophagectomy 
(removal of the esophagus via surgical intervention). As of now, no grouping of chemotherapeutic 
agents has been clearly demonstrated to be the most effective combination therapy in the EC patient 
population. Thus, on top of dealing with the adverse effects of an extensive surgery, patients are 
subjected to sporadically ineffective chemotherapy regimens. This expensive and rigorous periopera-
tive therapy protocol typically yields a short survival benefit over surgery alone (3, 4).
While we await a novel arsenal of therapeutic options in EC to be developed, what can surgeons, 
oncologists, scientists, and pathologists do to optimize first-line therapy to potentially improve sur-
vival rates? A straight-forward solution would involve research conducted in the recent past, current 
therapeutic options, and a more robust utilization of molecular diagnostics. Traditionally, proteomic 
expression assays are used in the targeted-therapeutic setting. For example, HER2 is a receptor 
associated with cancer progression and is expressed in approximately one of four gastroesophageal 
tumors (5, 6). Blocking HER2 with a drug such as trastuzumab would typically yield increased thera-
peutic efficacy and tumor regression (7). If a patient is prescribed trastuzumab and the tumor lacks 
HER2, the patient’s tumor is not likely to regress, leaving them only with toxic side effects such as 
cardiotoxicity (8). Thus, knowing whether this cellular surface protein is overexpressed in EC tumors 
is pertinent, which is why the expression status of HER2 is routinely ordered for this indication. This 
construct is also applicable with EGFR-targeted therapies. Even though the use of EGFR inhibi-
tors is considered “off-label” in EC, knowing whether or not the tumor expresses EGFR is crucial 
when prescribing tyrosine kinase inhibitors (9). Clinical trials testing novel immunotherapies are 
incorporating proteomic expression of a patient’s tumors before entering the trial, as programmed 
death-ligand 1 (PD-L1) expression has been strongly associated with increased benefit when using 
drugs targeting PD-L1 (expressed on the tumor) and even PD-1 (expressed on the T-cell) (10, 11). 
It is imperative to affirm that the target being shot at is actually there. In recent years, researchers 
FiGURE 1 | Visualize esophageal cancer therapeutic targets with 9-marker panel. Proteomic biomarkers affiliated with improved response to targeted therapy 
(green) or chemotherapy (red) drugs as well as resistance to various chemotherapeutic agents that are FDA approved for esophageal cancer (EC). Knowing the 
expression status of this 9-marker panel could assist oncologists in optimizing first-line patient management strategies for EC patients. Abbreviations: ERCC1, excision 
repair cross complementation group 1; TUBB3, tubulin beta-3; TOPO2A, topoisomerase 2α; TOPOI, type I topoisomerase; HER2, receptor tyrosine-protein kinase 
erbB-2; EGFR, epidermal growth factor receptor could assist; PD-L1, programmed death-ligand 1; RFC, reduced folate carrier; TS, thymidylate synthase.
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and clinicians have discovered proteomic biomarkers that have 
been linked to increased or decreased benefit when using certain 
classes of chemotherapy.
Of the 13 FDA-approved drugs for EC, 12 have affiliated bio-
markers that are associated with either improved or decreased 
benefit in solid tumor indications (Figure 1). Thymidylate syn-
thase (TS), if expressed in a tumor, is linked to decreased benefit 
when using the antimetabolite drugs capecitabine and fluorouracil 
(12). Excision repair cross complementation group 1 (ERCC1) is 
deemed a resistance marker to platinum-based therapies such as 
cisplatin, carboplatin, and oxaliplatin, which will have decreased 
benefit if expressed in a solid tumor (13–15). Topoisomerase 2α 
(TOPO2A) is an enzyme used in DNA repair and, if expressed, 
yields an increased benefit when using anthracyclines such as 
epirubicin and etoposide, drugs that target DNA repair mecha-
nisms (16). Type I topoisomerase (TOPOI) is another protein 
involved in DNA annealing, and if expressed in cancer, is associ-
ated with increased benefit when using topoisomerase inhibitors 
such as irinotecan, which is often prescribed in EC (17, 18). 
Tubulin beta-3 (TUBB3) is another resistance marker that, when 
expressed, is linked with decreased benefit when using taxanes 
such as paclitaxel and docetaxel (19, 20). Reduced folate carrier 
(RFC), when expressed, is associated with improved benefit while 
using leucovorin, a drug that is used to a lesser extent in this indi-
cation but is still FDA approved for EC (21). Finally, as previously 
mentioned, HER2 is a companion biomarker to anti-HER2 drug 
trastuzumab, which is FDA approved in the first-line setting in 
EC. When HER2 is overexpressed, trastuzumab is more effica-
cious in halting tumor progression (22). Thus, 92% of the drugs 
that are FDA approved in EC have a concomitant biomarker that 
is associated with either increased or decreased benefit. The only 
drug in the cadre of EC therapy that lacks a proven diagnostic 
biomarker today is mitomycin.
In many cancers, there is an issue with the amount of tis-
sue available for histological scrutiny before chemotherapy has 
been administered. However, a large percentage of EC patients 
undergo complete resection of the esophagus before adjuvant 
chemotherapy, which provides a large, unadulterated tumor 
with reliable protein expression because it remains unaffected 
by chemotherapy. These tumor samples contain ample amounts 
of tissue that could be used for outsourced diagnostics via 
private biotech companies or even in-house pathology-based 
assays. In this instance, oncologists and pathologists would 
order a 9-marker panel of proteomic expression assays covering 
virtually every drug in the EC therapy cache as an auxiliary to 
assembling first-line therapy, thereby improving the probability 
of prescribing an efficacious regimen (Figure  1). It would be 
more difficult to reliably analyze the tumors of patients who 
are treated with neoadjuvant chemotherapy before resection, as 
the only source of tissue for these patients is accessed via endo-
scopic pinch biopsies which are usually taken before chemo is 
administered.  There are other pathology-based services that are 
required from this tissue, none of which are proteomic diagnos-
tics for augmenting first-line therapy. However, if an oncologist 
was inclined to prescribe a combination of cisplatin + fluoro-
uracil, it would be prudent to stain two formalin-fixed paraffin 
embedded sections for TS and ERCC1 to observe if the tumor 
possesses resistance markers for these drugs. Protein detection 
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of two markers could potentially be determined by immuno-
histochemistry (IHC) of pinch biopsies only a few micrometers 
thick and would not necessitate using many large sections of 
tumor to detect the whole 9-marker panel. One of the side 
effects of cisplatin is that it can induce ototoxicity, rendering 
some patients completely deaf (23). Proteomics may be a use-
ful strategy in avoiding unnecessary adverse events in the case 
of patients having a limited response to chemotherapy due to 
resistance elements in the tumor. Physicians assume the risk of 
low response rates and decreased efficacy by prescribing these 
chemotherapies in a relatively blind manner. There is little to 
lose by treating these patients with enhanced precision medicine 
because effective management of EC patients is one of the most 
difficult battles in the field of oncology.
Immunotherapy has tremendous potential to improve 
EC patient care based upon its impressive performance in 
other solid tumor types (24). Immediate screening for PD-L1 
postesophagectomy would be most helpful in determining 
whether or not patients are ideal candidates for immunotherapy 
trials. PD-L1 is expressed in 40% of gastroesophageal cancers, 
so it cannot be presumed that all EC patients would be suitable 
candidates for PD-L1-targeted immunotherapy (25). However, 
placing PD-L1-positive patients in an immunotherapy clinical 
trial could potentially improve survival rates while simultane-
ously advancing this field of study.
The 9-marker panel proposed here (Figure  1) has not been 
specifically analyzed in a tumor registry or clinical trial, so 
whether or not this method would translate to improved patient 
outcomes is still unknown. However, commercial diagnostic 
companies are beginning to publish the results of test registries 
in which patient management strategies derived from their 
diagnostic platforms have translated into improved outcomes. 
For example, the New England Journal of Medicine published 
a study in 2015 demonstrating how a 21-gene expression test 
identified breast cancer patients who would receive no benefit 
from additional chemotherapy. Clinical use of this assay lowered 
the rate of recurrence as well as the number of adverse events in 
this population of breast cancer patients by treating them with 
endocrine therapy alone (26). Prognostic information derived 
from molecular diagnostics was demonstrated in a 2016 study, 
where investigators quantified HER2 in breast cancer samples 
with a commercial mass spectrometry assay as opposed to the 
+1, +2, and +3 quantification via IHC. Receptor tyrosine-protein 
kinase erbB-2 expression levels greater than 2,200 amol/μg was 
associated with significant extended disease-free survival and 
overall survival in adjuvant cases as well as longer overall survival 
in metastatic cases when treated with HER2-targeted therapy 
(27). So, quantitative proteomics also has the potential to predict 
the level of response to affiliated therapies.
Weighing the costs and expected benefits of molecular diag-
nostics is an unfortunate reality that must be considered when 
determining its feasibility when configuring first-line therapy 
strategies. Most oncology-based platforms can be extremely 
expensive, with tests ranging from $2,500–$34,000. Many payers 
are reluctant to offer even fractional reimbursement for diagnostic 
assays when there is no enough evidence of significant improve-
ment in patient outcomes associated with the results of their 
tests. Oftentimes insurance will not offer any reimbursement to 
biotech companies for running their commercial assay in the 
clinical setting. However, most companies have financial assis-
tance programs to more readily deliver results of their platform 
to oncologists and their patients. An alternate strategy would be 
the utilization of medical center pathology departments, where 
they should be able to perform IHC on this 9-marker panel 
using reimbursable ICD-9 codes at around $50–$200 per IHC 
stain. This would be an economical and expedited way to have 
information on the nine proteins that are relevant to EC therapy 
for a fraction of the price of an outsourced test.
To summarize, a diagnosis of EC is an uphill battle, no matter 
the stage the patient presents on day one. If a patient is fit for 
perioperative chemotherapy, screening their tumor for HER2, 
EGFR, PD-L1, ERCC1, TUBB3, TS, RCF, TOPOI, and TOPO2A 
would be a straightforward way to inform the oncologist which 
proteins in the patient’s tumors are prime targets and which 
proteins could potentially act as resistance molecules for EC drug 
options (Figure 1). RNAseq and genomic sequencing are often 
utilized by molecular diagnostic companies; however, the data in 
those assays not only provide extraneous information with little 
clinical utility to-date but also act as a surrogate for what is actu-
ally occurring in the proteome at the day of diagnosis. Therefore, 
screening EC tumors with the proposed 9-marker panel would 
inform oncologists of the expression status of the proteins 
associated with clinical utility in real time, which would assist in 
determining the combination of targeted and chemotherapies to 
optimize first-line therapy.
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